Progress in the treatment of ovarian cancer—lessons from homologous recombination deficiency—the first 10 years
Epithelial ovarian cancer
Opportunities in immunotherapy of ovarian cancer
The molecular pathology of ovarian serous borderline tumors†
Management of borderline ovarian tumors
Molecular imaging in ovarian cancer
Neoadjuvant chemotherapy in ovarian cancer revisited
Anti-angiogenic agents in ovarian cancer
PARP inhibitors in ovarian cancer
Low-grade serous carcinoma of the ovary or peritoneum
Clear-cell carcinoma of the ovary
Mucinous epithelial ovarian carcinoma
Optimal primary therapy of ovarian cancer
Recurrent ovarian cancer
Patient-reported outcomes (PRO) in ovarian cancer clinical trials—lost opportunities and lessons learned
Advanced ovarian cancer